Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JWK003
- Development stage
- Phase 1
- Lead developer
- Chengdu Genevector Biotechnology
- Modality
- Gene Therapies
- Administration
- Intranasal
01
Overview
JWK003 is an adeno-associated virus (AAV)-mediated gene therapy being developed by West China Hospital of Sichuan University for the treatment of mild Alzheimer's disease. Administered via a nasal spray, the therapy utilizes an AAV vector to deliver a therapeutic transgene directly to the central nervous system, bypassing the blood-brain barrier through the olfactory and trigeminal nerve pathways. It is currently being evaluated in a Phase 1 clinical trial in China to assess its safety, tolerability, and biological activity in adults with mild cognitive impairment or early-stage Alzheimer's disease, with assessments including cognitive function, neuropsychiatric symptoms, and biomarker levels.
Beyond the preview
Go deeper on JWK003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JWK003.